Skip to main content

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Publication ,  Journal Article
Stein, BL; Gotlib, J; Arcasoy, M; Nguyen, MH; Shah, N; Moliterno, A; Jamieson, C; Pollyea, DA; Scott, B; Wadleigh, M; Levine, R; Komrokji, R ...
Published in: J Natl Compr Canc Netw
April 2015

The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2(V617F) and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

April 2015

Volume

13

Issue

4

Start / End Page

424 / 434

Location

United States

Related Subject Headings

  • Thrombosis
  • Thrombocythemia, Essential
  • Splenomegaly
  • Receptors, Thrombopoietin
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Polycythemia Vera
  • Oncology & Carcinogenesis
  • Janus Kinases
  • Janus Kinase 2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stein, B. L., Gotlib, J., Arcasoy, M., Nguyen, M. H., Shah, N., Moliterno, A., … Mesa, R. A. (2015). Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw, 13(4), 424–434. https://doi.org/10.6004/jnccn.2015.0058
Stein, Brady L., Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, et al. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.J Natl Compr Canc Netw 13, no. 4 (April 2015): 424–34. https://doi.org/10.6004/jnccn.2015.0058.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr;13(4):424–34.
Stein, Brady L., et al. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.J Natl Compr Canc Netw, vol. 13, no. 4, Apr. 2015, pp. 424–34. Pubmed, doi:10.6004/jnccn.2015.0058.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr;13(4):424–434.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

April 2015

Volume

13

Issue

4

Start / End Page

424 / 434

Location

United States

Related Subject Headings

  • Thrombosis
  • Thrombocythemia, Essential
  • Splenomegaly
  • Receptors, Thrombopoietin
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Polycythemia Vera
  • Oncology & Carcinogenesis
  • Janus Kinases
  • Janus Kinase 2